Q-Symbio study - Q10facts

Q-Symbio is the abbreviated name for the two-year multi-center, randomized, double-blindA double-blind study is a study in which neither the investigators nor the study participants know which participants are receiving the active treatment and which participants are receiving the control treatment until the study has been completed and the seal on the code has been broken. More, placebo-controlled study of Coenzyme Q10Coenzyme Q10 molecules are fat-soluble molecules that are both synthesized in the body and ingested in the diet and in supplements. Coenzyme Q10 is synthesized in the body in the same biological pathway as cholesterol. Bio-synthesis of Coenzyme Q10 begins to decline once humans reach their adult years. The reduced production of Coenzyme Q10 cannot be compensated in any practical... More supplements as an adjunct treatmentAlso called adjuvant treatment and adjunctive treatment, adjunct treatment is additional treatment together with conventional medical treatment. Adjunct treatment is the use of daily Coenzyme Q10 supplementation together with conventional medical treatment for heart failure, diabetes, hypertension, degenerative diseases, and low-energy syndrome diseases. More of chronic heart failureThe Mayo Clinic defines heart failure, also known as congestive heart failure and/or chronic heart failure, as the failure of the heart muscle to pump blood to the body adequately. In other words, heart failure is not a heart attack, and it is not death from heart disease, which its name might seem to imply. Heart failure is a condition... More patients. The name reflects the focus of the study on the SYMptoms, BIomarker status (BNP), and long-term Outcomes (hospitalizations and mortality) of the supplementation.
The data from the Q-Symbio studyQ-Symbio is the abbreviated name for the two-year multi-center, randomized, double-blind, placebo-controlled study of Coenzyme Q10 supplements as an adjunct treatment of chronic heart failure patients. The name reflects the focus of the study on the SYMptoms, BIomarker status (BNP), and long-term Outcomes (hospitalizations and mortality) of the supplementation. The data from the Q-Symbio study show that long-term supplementation with... More show that long-term supplementation with 300 milligrams per day is safe, improves symptoms and survival, and reduces the risk of major adverse cardiovascular events.